The IMAP Study Improving Management of Mildly Abnormal Pap Smears
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00119509|
Recruitment Status : Unknown
Verified April 2007 by University of Sydney.
Recruitment status was: Active, not recruiting
First Posted : July 13, 2005
Last Update Posted : April 25, 2007
The study compares the psychosocial outcomes of different management strategies for women with minor atypia (including ‘HPV effect’) detected on Pap smears: conventional management (a repeat Pap smear at 6 months) versus Human papillomavirus (HPV) DNA testing, a new method proposed for the management of minor atypia and the informed choice of either management supported by a decision aid.
The study examines women’s informed preferences for each of these options and compares the psychosocial outcomes in women who are or are not given the choice of management.
HPV DNA testing offers considerable changes to the management of women with minor atypia and there is evidence from the USA which suggests that the use of HPV DNA testing as a triage strategy is effective for women within this group (Solomon et al 2001). The introduction of HPV DNA testing may bring both benefits and harms to women. These harms and benefits are not well understood. Examination of the psychosocial outcomes of HPV DNA testing compared to conventional management and women’s preferences for each is needed to guide decisions concerning HPV DNA testing in cervical screening in Australia and also internationally.
|Condition or disease||Intervention/treatment||Phase|
|Cervix Neoplasms||Procedure: HPV DNA testing Procedure: Conventional management (repeat Pap smear at 6 months) Procedure: Decision aid with choice of management||Phase 3|
Women diagnosed with minor atypia following a routine Pap smear will be randomised into one of the three management arms of the study (a) HPV DNA test, (b) Decision Aid (DA) with choice of management, or (c) a 6 month repeat Pap smear (conventional management). Women who are allocated to the HPV DNA arm and the repeat Pap will receive standard information about their management strategy. Women allocated to the decision aid arm will receive information about HPV DNA testing and 6 month repeat Pap in a decision aid format as an adjunct to usual clinical care and asked to indicate their preference for management. Women in this arm will receive the management strategy of their choice (HPV DNA or repeat Pap). The impact of the Decision Aid will be assessed and psychosocial impact of each management strategy will be followed up over the short, medium and long term.
Management and Clinical outcomes: Data will be collected on the taking and timing of Pap smears, HPV testing and colposcopy as well as findings for each of these tests and any subsequent treatment.
Psychosocial outcomes: Measures will be administered by postal questionnaire at multiple time points across the study. There will be 3 questionnaires: (1) Baseline questionnaire – for all participants recruited into the study; (2) Decision-making evaluation – to assess decision-making in all groups and the impact of the decision aid; (3) Psychosocial impact questionnaire – brief questionnaire (taking approximately 10 minutes to complete) sent at multiple time points to assess the psychosocial impact over time (2 weeks, 3, 6 and 12 months).
Quality of life assessment: Participants will be invited to take part in an interview at 1 month and 12 months post testing (HPV testing or repeat Pap smear) to assess quality of life using standardised validated QOL measures. Interviews will be carried out by an experienced female researcher. Study participants will be given the option to participate in the interview and will be under no obligation to take part if they do not wish to.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Official Title:||HPV DNA Testing Versus Conventional Management for Women With Minor Atypia on Pap Smear: Psychosocial and Quality of Life Outcomes and Development of a Decision Analytic Model|
|Study Start Date :||January 2004|
|Estimated Study Completion Date :||April 2008|
- Psychosocial wellbeing assessed using psychometric scales including (a) global measures of psychological health (STAI, SF36)and (b) measures specific to cervical screening.
- Quality of Life (Utility) Assessment two stage standard gamble (SG) technique produces a utility score between 0 and 1.
- Clinical outcomes: results of follow-up Pap smear and Colposcopy and HPV testing
- Management preference: women’s preference for HPV or repeat Pap testing measured by a Decision Aid.
- Decision Aid evaluation: Measure the impact of the DA of knowledge, decisional conflict, and satisfaction with decision making
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00119509
|Australia, New South Wales|
|North Coast Community Health Centre|
|Port Macquarie, New South Wales, Australia, 2444|
|Family Planning Association|
|Sydney, New South Wales, Australia, 2000|
|Taree Community Health Centre|
|Taree, New South Wales, Australia, 2430|
|Illawarra Women's Health Centre|
|Warilla, New South Wales, Australia, 2528|
|Family Planning Queensland|
|Brisbane, Queensland, Australia, 4006|
|Australia, South Australia|
|Adelaide, South Australia, Australia, 5068|
|Australia, Western Australia|
|Family Planning Western Australia|
|Perth, Western Australia, Australia, 6865|
|Study Chair:||Kirsten McCaffery, PhD||University of Sydney|
|Study Director:||Les Irwig, PhD||University of Sydney|
|Principal Investigator:||Glenn Salkeld, PhD||University of Sydney|
|Principal Investigator:||Alexandra Barratt, PhD||University of Sydney|
|Principal Investigator:||Kirsten Howard, Masters||University of Sydney|
|Principal Investigator:||Edith Weisberg, Medicine||Family Planning Association|